Form 4: Kura Oncology Director Diane Parks Receives Significant Stock Option Grant

Kura Oncology, Inc. Director Diane L. Parks was granted options to purchase 28,500 shares of common stock at an exercise price of $6.57, vesting in one year.

Summary

• Diane L. Parks, a Director of Kura Oncology, Inc. (KURA), was granted stock options on June 5, 2025.
• She acquired options to purchase 28,500 shares of Kura Oncology common stock.
• The exercise price for these options is $6.57 per share.
• The options are scheduled to vest in full on the one-year anniversary of the grant date, which is June 5, 2026.
• The options have a long-term expiration date of June 4, 2035.
• Following this transaction, Diane Parks beneficially owns 28,500 derivative securities (options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns management's interests with shareholders and is a routine part of compensation, indicating stability in governance.

Positives

• The grant of stock options to Director Diane L. Parks aligns her financial interests with those of shareholders, incentivizing long-term company performance and value creation.
• The options have a long expiration date of June 4, 2035, providing a significant window for potential value realization based on future stock price appreciation.

Future Outlook

The options granted to Director Diane L. Parks are set to vest in full on June 5, 2026, indicating a future milestone for her equity compensation and continued alignment with the company's performance.

Industry Context

The granting of stock options to directors is a common and standard practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages designed to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of 28,500 stock options to a director is a typical form of equity compensation within the biotechnology sector.
• Without specific peer group compensation data for similar-sized oncology companies (e.g., Mirati Therapeutics, Blueprint Medicines), a direct quantitative comparison of the size of this specific grant to industry benchmarks is not possible from this filing alone.

Related Party Transactions

• The grant of stock options to Diane L. Parks, a director of Kura Oncology, Inc., constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be viewed positively as it aligns the director's financial interests with the long-term performance of the company, potentially leading to increased shareholder value.

Next Steps

• The options granted to Diane L. Parks are scheduled to vest in full on June 5, 2026.

Key Dates

Recommendation

Keywords

Kura Oncology, KURA, stock options, insider transaction, Form 4, Diane Parks, director, equity compensation, beneficial ownership